PNH
Clinical trials for PNH explained in plain language.
Never miss a new study
Get alerted when new PNH trials appear
Sign up with your email to follow new studies for PNH, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for PNH patients: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of pegcetacoplan in people with PNH, a rare blood disorder. Participants must have completed a prior pegcetacoplan study and shown benefit. The main goal is to track side effects over time.
Matched conditions: PNH
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New drug combo for rare blood disease under safety review
Disease control OngoingThis study looks at the long-term safety of danicopan when added to standard treatments for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers will analyze data from 50 adults already taking danicopan alongside eculizumab or ravulizumab. The goal is to …
Matched conditions: PNH
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New study tracks Long-Term safety of danicopan combo for rare blood disorder
Disease control OngoingThis study looks at the long-term safety of adding danicopan to standard treatments (ravulizumab or eculizumab) for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers will analyze data from 50 adults already enrolled in a PNH registry to tra…
Matched conditions: PNH
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 05, 2026 11:56 UTC